Testing YK012 for primary membranous nephropathy
Treatments studied
Part of Kidney & urinary clinical trials.
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with primary membranous nephropathy by a kidney biopsy in the last 10 years.
- You have high protein levels in your urine over 24 hours.
- Your kidney function is good (eGFR of 60 or higher).
- You have not had any prior treatments for this condition with other specific therapies.
- You are willing to follow the study schedule and give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called B007 for people with primary membranous nephropathy, a kidney condition. It aims to see if B007 can help reduce protein in the urine and protect kidney function.
This trial tests an experimental drug called YK012 for people with a serious type of kidney disease called primary membranous nephropathy. It aims to see if the drug is safe and helps when other treatments have stopped working.
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
This study looks at how well a treatment works for people with primary membranous nephropathy (PMN), a kidney condition. It is meant for patients who still have high protein in their urine despite taking standard blood pressure medicines.
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
This study tests a new treatment called FKC289 for people with membranous nephropathy (a kidney disease) that has not improved or has returned after other treatments. It aims to see if the treatment is safe and helps reduce protein in the urine.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.